United Community Bank Has $202,000 Stake in McKesson Co. (NYSE:MCK)

United Community Bank raised its stake in McKesson Co. (NYSE:MCK) by 20.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 376 shares of the company’s stock after buying an additional 65 shares during the quarter. United Community Bank’s holdings in McKesson were worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Lindbrook Capital LLC raised its position in shares of McKesson by 1.7% during the first quarter. Lindbrook Capital LLC now owns 1,133 shares of the company’s stock worth $608,000 after purchasing an additional 19 shares during the period. Douglass Winthrop Advisors LLC raised its position in shares of McKesson by 1.4% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 1,512 shares of the company’s stock worth $700,000 after purchasing an additional 21 shares during the period. Addison Advisors LLC raised its position in shares of McKesson by 7.9% during the fourth quarter. Addison Advisors LLC now owns 299 shares of the company’s stock worth $138,000 after purchasing an additional 22 shares during the period. Evergreen Wealth Solutions LLC raised its position in shares of McKesson by 1.2% during the fourth quarter. Evergreen Wealth Solutions LLC now owns 1,931 shares of the company’s stock worth $894,000 after purchasing an additional 22 shares during the period. Finally, First Personal Financial Services raised its position in shares of McKesson by 1.5% during the first quarter. First Personal Financial Services now owns 1,514 shares of the company’s stock worth $813,000 after purchasing an additional 23 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MCK. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 2nd. Barclays raised their price target on McKesson from $571.00 to $596.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft reduced their target price on McKesson from $547.00 to $545.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Citigroup lifted their target price on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Finally, TD Cowen lifted their target price on McKesson from $563.00 to $652.00 and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $596.00.

McKesson Price Performance

MCK stock traded down $0.01 during midday trading on Wednesday, reaching $586.80. 61,776 shares of the stock were exchanged, compared to its average volume of 697,217. The stock has a market capitalization of $76.25 billion, a PE ratio of 26.22, a P/E/G ratio of 1.38 and a beta of 0.45. McKesson Co. has a 52 week low of $395.30 and a 52 week high of $612.17. The company has a fifty day moving average price of $572.90 and a 200 day moving average price of $532.34.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $6.18 earnings per share for the quarter, missing analysts’ consensus estimates of $6.34 by ($0.16). The firm had revenue of $76.36 billion for the quarter, compared to the consensus estimate of $79.32 billion. McKesson had a negative return on equity of 245.88% and a net margin of 0.97%. The company’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.19 EPS. As a group, analysts anticipate that McKesson Co. will post 31.53 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, July 1st. Shareholders of record on Monday, June 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend was Monday, June 3rd. McKesson’s dividend payout ratio is presently 11.08%.

Insider Transactions at McKesson

In other news, Director Susan R. Salka sold 606 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $558.04, for a total value of $338,172.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Susan R. Salka sold 606 shares of McKesson stock in a transaction on Friday, May 10th. The shares were sold at an average price of $558.04, for a total value of $338,172.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas L. Rodgers sold 789 shares of McKesson stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $557.40, for a total transaction of $439,788.60. Following the completion of the sale, the executive vice president now owns 7,909 shares of the company’s stock, valued at approximately $4,408,476.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,567 shares of company stock worth $16,691,841. Company insiders own 0.11% of the company’s stock.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.